Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAPCells Vaccine in Advanced Malignant Melanoma
NCT06152367Phase 2Completed
- Sponsor
- Universidad de Chile
- Start
- Jan 2001
- Primary completion
- Oct 2004
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TAPCells in Malignant Melanoma (MM), sponsored by Universidad de Chile. Primary endpoints: Incidence of treatment-emergent adverse events at 2 years, Local immune response measurement by DTH at 2 years and 8 more. Started Jan 2001; status: completed.
02
Drugs
TAPCells
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT06152367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06152367.